<DOC>
	<DOCNO>NCT02148146</DOCNO>
	<brief_summary>This clinical study design evaluate safety benefit fish oil base fat emulsion treatment liver disease associate prolonged use intravenous nutrition .</brief_summary>
	<brief_title>Use Omega 3 Oil Emulsion Parenteral Nutrition Associated Cholestasis</brief_title>
	<detailed_description>Specific Aims Study 1 . To determine safety profile intravenous omega-3 fat emulsion ( Omegaven™ ) 2 . To determine establish PN associate liver disease reverse progression halt use parenteral fat emulsion prepare fish oil measure normalization serum level hepatic enzymes bilirubin .</detailed_description>
	<mesh_term>Cholestasis</mesh_term>
	<criteria>1 . Age &lt; 18 year old 2 . Patients PN dependent ( unable meet nutritional need solely enteral nutrition ) expect require PN least another 30 day , may inpatient outpatient 3 . Patients consider eligible study participation must parenteral nutrition associate liver disease ( PNALD ) define direct bilirubin 2 mg/dl . Other cause liver disease exclude . A liver biopsy necessary treatment 4 . Direct bilirubin &gt; 2.0 mg/dl 5 . Signed patient inform consent 6 . The patient must utilize standard therapy prevent progression his/her liver disease include surgical treatment , cyclic PN , avoid overfeeding , reduction/removal copper manganese PN , advancement enteral feeding , use ursodiol ( i.e. , Actigall® ) 1 . Pregnancy 2 . Other cause chronic liver disease ( Hepatitis C , Cystic fibrosis , biliary atresia , alpha 1 antitrypsin deficiency ) 3 . Enrollment clinical trial involve investigational agent ( unless approve designated physician multidisciplinary team ) 4 . The parent guardian child unwilling provide consent assent 5 . Patients know allergic fish egg protein patient follow contraindication Omegaven™ use : Impaired lipid metabolism Severe hemorrhagic disorder Unstable diabetes mellitus Collapse shock Stroke/embolism Recent cardiac infarction Undefined coma status</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>short bowel syndrome</keyword>
	<keyword>intestinal failure</keyword>
	<keyword>total parenteral nutrition associate cholestasis</keyword>
</DOC>